Cargando…

Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia

Patients with relapsed acute myeloid leukemia (AML) have unfavorable prognosis and require innovative therapeutic approaches. In this study we used fludarabine combined with a middle dose of cytosine arabinoside (Ara-C), mitoxantrone and granulocyte-colony stimulating factor (G-CSF) as a salvage the...

Descripción completa

Detalles Bibliográficos
Autores principales:	LUO, SHENG, CAI, FANGFANG, JIANG, LEI, ZHANG, SHENGHUI, SHEN, ZHIJIAN, SUN, LAN, GAO, SHENMENG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570250/ https://www.ncbi.nlm.nih.gov/pubmed/23407597 http://dx.doi.org/10.3892/etm.2013.917

Ejemplares similares

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia
por: Bi, Laixi, et al.
Publicado: (2018)

FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
por: Yılmaz Bengoa, Şebnem, et al.
Publicado: (2017)

P545: VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Burkart, Madelyn, et al.
Publicado: (2023)

Treatment of Relapsed Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2020)

Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study
por: Bao, Y., et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

The “7+3” regimen in acute myeloid leukemia
por: Rowe, Jacob M.
Publicado: (2022)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia
por: Dadrass, Farinoosh, et al.
Publicado: (2022)

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
por: Feng, Yimei, et al.
Publicado: (2023)

Isolated Intracranial Myeloid Sarcoma Occurring as Relapse in Acute Myeloid Leukemia
por: Narayanan, Geetha, et al.
Publicado: (2017)

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study
por: Xu, Jun, et al.
Publicado: (2018)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Anders, Brandi, et al.
Publicado: (2017)

Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis
por: Cao, Susu, et al.
Publicado: (2023)

A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia
por: Li, Yuhang, et al.
Publicado: (2021)

HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia
por: Hu, Xiaoxia, et al.
Publicado: (2015)

Relapsing acute myeloid leukemia presenting as hypopyon uveitis
por: Hegde, Sapna P, et al.
Publicado: (2011)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia
por: Wang, Jingbo, et al.
Publicado: (2018)

Colonic Myeloid Sarcoma as a Rare Presentation of Relapsed Acute Myeloid Leukemia
por: Phatharacharukul, Parkpoom, et al.
Publicado: (2020)

Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics
por: Sahoo, Ranjit Kumar, et al.
Publicado: (2013)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Clonal evolution of acute myeloid leukemia from diagnosis to relapse
por: Vosberg, Sebastian, et al.
Publicado: (2019)

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia
por: Rapaport, Franck, et al.
Publicado: (2021)

Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
por: Beziat, Guillaume, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Convergent Epigenetic Evolution Drives Relapse in Acute Myeloid Leukemia
por: Nuno, Kevin A., et al.
Publicado: (2023)

CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
por: Farge, Thomas, et al.
Publicado: (2023)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
por: Piccini, Matteo, et al.
Publicado: (2021)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

Relapsed acute myeloid leukemia presenting as conjunctival myeloid sarcoma: a case report
por: Park, Joong Hyun, et al.
Publicado: (2022)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ltn3buvv0914cg26naavk12qls